Arbutus Biopharma Overview
Valuation check: ABUS's ROE is 59.16%, above the Healthcare sector average of 21.67%.
Get informed when a big investor buys or sells
+ Follow59.16%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Arbutus Biopharma (ABUS) currently reports a ROE of 59.16%. That is above the Healthcare sector average of 21.67%. Use the charts on this page to explore Arbutus Biopharma's ROE history and peer comparisons.
Arbutus Biopharma's ROE of 59.16% is higher than the Healthcare sector average of 21.67%. That is roughly 173.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Arbutus Biopharma's current 59.16% should be judged against Healthcare norms (sector average: 21.67%) and against ABUS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 59.16%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Arbutus Biopharma, and consider following ABUS for alerts when major investors trade the stock.
Arbutus Biopharma is classified in the Healthcare sector. On ROE, it currently shows 59.16% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ABUS with unrelated industries.
